Abstract
Introduction Polycystic Ovary Syndrome (PCOS) is the most frequent endocrine syndrome in women of the reproductive age groupassociated with metabolic syndrome and TypeIIDiabetesMalitus (TIIDM). Purpose of the study was to evaluate if level of serum irisin which is involved in energy metabolism could be used as biomarker for identifying high risk category for pre-clinical detection of diabetes in PCOS.
Methods Total 27 obese PCOS, 27 non-obese PCOS, and 27 healthy control (HC: 11 obese and 16 non-obese) study subjects between the age group 15-30 years were recruited in the study. Obese and non-obese category was divided based on BMI. Serum irisin, fasting insulin, fasting glucose and other reproductive hormonal profiles were estimated. Cut offs for serum irisin and insulin level were determined based on levels in healthy control.
Result None of the subject was diagnosed having diabetes at the time of sampling. Both obese and non-obese PCOS showed non-significant lower irisin level than corresponding healthy control (42.27±31.38 vs 51.56±22.7,P=0.4 and 34.89±21.58 vs 40.90±16.444,P=0.4 respectively). However only obese PCOS showed statistically significant association with lower irisin level when median value of the corresponding healthy control was used as cut off (81.5% vs 45%, P=0.047* and 70.3% vs 50%,P=0.21 in PCOS vs HC of obese and non-obese group respectively). Segregating PCOS subjects into two category either normal or below the lower limit of normal serum irisin level(mean-1.64*z of corresponding HC), 100% of obese PCOS subjects having irisin below the lower normal limit showed insulin resistance (>mean+2SD of non obese HC) while the same in obese PCOS subjects having irisin level above the lower limit was only 20% (P=0.006). However no such association was observed in non-obese PCOS subjects when similarly categorized based on irisin level (33% vs 22% respectively, P= 1).
Conclusion The result suggests that obese PCOS with serum irisin level below lower limit of normal range could be segregated as high risk category for closely follow up to detect incidence of diabetes in early time point or taking any preventive measure in early stage. A prospective study with larger sample size is required to substantiate the observation of the pilot study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Department of Health Research (DHR), Ministry of Health and Family Welfare (MOHFW), Government of India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional ethical committee of Pt. J.N.M.Medical College Raipur, Chhattisgarh, India gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
